Rituximab in Autoimmune CNS Disease
Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Pediatric Neurology Briefs Publishers,
2014-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|